test

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions

Endometrial Cancer | Fatigue | Neurotoxicity

What is the purpose of this trial?

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether pelvic radiation therapy is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.

PURPOSE: This randomized phase III trial is studying pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer.



Participation Guidelines

Age:
18 Years and older
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Gynecologic Oncology Group
National Cancer Institute (NCI)
Dates:
March 2009
Last Updated:
February 3, 2012
Study HIC#:
0908005553

Clinicaltrials.gov ID: NCT00807768